{"ModuleTitle": "Company Description", "CompanyName": "Geron Corporation", "Symbol": "GERN", "Address": "919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY, California, 94404, United States of America", "Phone": "6504737700", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a late-stage clinical biopharmaceutical company that is focused on the\r\ndevelopment and potential commercialization of imetelstat, an innovative\r\ntherapeutic for hematologic myeloid malignancies. We have global rights to\r\nimetelstat, a first-in-class telomerase inhibitor, which was discovered and\r\ndeveloped at Geron. We believe targeting telomerase has the potential to inhibit\r\nthe uncontrolled proliferation of malignant progenitor cells in hematologic\r\nmyeloid malignancies to reduce dysfunctional blood cell production and enable\r\nrecovery of normal blood cell production. Data reported from our Phase 2/3\r\nclinical trial in lower risk myelodysplastic syndromes, or MDS, indicate\r\nimetelstat may induce meaningful and durable transfusion independence and\r\nincreases in hemoglobin levels, suggesting potential recovery of normal blood\r\ncells occurring in the bone marrow, or hematopoiesis.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f12%2f0001564590-20-010449.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Aleksandra Rizo", "title": "Chief Medical Officer & Executive Vice President"}, {"name": "Andrew J. Grethlein", "title": "Chief Operating Officer & Executive Vice President"}, {"name": "John A. Scarlett", "title": "Chairman, President & Chief Executive Officer"}, {"name": "Melissa A. Kelly Behrs", "title": "Chief Business Officer & Executive Vice President"}, {"name": "Olivia K. Bloom", "title": "Chief Financial Officer, Treasurer & Executive VP"}], "Number_of_employees": [], "Subsidiaries": ["NO INFO"]}